Apogee Therapeutics (APGE) Current Assets (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Current Assets data on file, last reported at $1.1 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.1 billion, up 105.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 105.89% YoY), and the FY2025 annual result was $741.4 million, up 39.95% from the prior year.
• Current Assets advanced to $1.1 billion in Q1 2026 per APGE's latest filing, from $741.4 million in the prior quarter.
• Over five years, Current Assets peaked at $1.1 billion in Q1 2026 and troughed at $130.7 million in Q2 2023.
• A 5-year average of $543.6 million and a median of $529.7 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets surged 421.82% in 2024, then slumped 36.45% in 2025.
• A 5-year view of Current Assets shows it stood at $152.1 million in 2022, then soared by 162.02% to $398.4 million in 2023, then surged by 32.96% to $529.7 million in 2024, then surged by 39.95% to $741.4 million in 2025, then soared by 44.84% to $1.1 billion in 2026.
• Business Quant data shows APGE's Current Assets at $1.1 billion in Q1 2026, $741.4 million in Q4 2025, and $540.1 million in Q3 2025.